https://doi.org/10.4081/reumatismo.2022.1489
Disseminated cutaneous herpes simplex infection after COVID-19 vaccination in a rheumatoid arthritis patient: a case report and review
Submitted: 16 March 2022
Accepted: 7 May 2022
Published: 13 September 2022
Accepted: 7 May 2022
Abstract Views: 1596
PDF: 828
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Since COVID-19 vaccination started in December 2020, different side effects were reported. This case report describes the possibility of developing disseminated herpes simplex infection after COVID-19 vaccine in a patient with rheumatoid arthritis. In this case report, we describe a 63-year-old Iranian female. She was a known case of seronegative rheumatoid arthritis and presented with generalized papulo-pustular itchy and painful skin lesions which appeared about seven days after the second dose of Sinopharm BIBP COVID-19 vaccine (BIBP-CorV). A biopsy of the skin lesions revealed acantholysis, neutrophils, and enlarged keratinocytes with eosinophilic intra-nuclear inclusions. Findings were consistent with herpes simplex infection. She was successfully treated by acyclovir. Disseminated cutaneous herpes simplex infection may have been triggered by COVID-19 vaccination. Reactivation of herpes virus after COVID-19 vaccines was reported in both rheumatic patients and other individuals. Whether having an underlying autoimmune inflammatory disorder could be an additional risk factor is still unknown.
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020 [Epub ahead of print].
Fathy RA, McMahon DE, Lee C, et al. Varicella‐zoster and herpes simplex virus reactivation post‐COVID‐19 vaccination: a review of 40 cases in an International Dermatology Registry. J Eur Acad Dermatol Venereol. 2021 [Epub ahead of print].
DOI: https://doi.org/10.1111/jdv.17646
Rodríguez-Jiménez P, Chicharro P, Cabrera L-M, et al. Varicella-Zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: report of 5 cases. JAAD Case Rep. 2021; 12: 58-9.
DOI: https://doi.org/10.1016/j.jdcr.2021.04.014
Muhie OA, Adera H, Tsige E, Afework A. Herpes zoster following covaxin receipt. Int Med Case Rep J. 2021; 14: 819.
DOI: https://doi.org/10.2147/IMCRJ.S345288
Shah S, Baral B, Chamlagain R, et al. Reactivation of herpes zoster after vaccination with an inactivated vaccine: A case report from Nepal. Clin Case Rep. 2021; 9: e05188.
DOI: https://doi.org/10.1002/ccr3.5188
Atiyat R, Elias S, Kiwan C, et al. Varicella-Zoster virus reactivation in AIDS patient after Pfizer-BioNTech COVID-19 vaccine. Cureus. 2021; 13(12). [Epub ahead of print].
DOI: https://doi.org/10.7759/cureus.20145
Bostan E, Yalici-Armagan B. Herpes zoster following inactivated COVID-19 vaccine: a coexistence or coincidence? J Cosmet Dermatol. 2021 [Epub ahead of print].
DOI: https://doi.org/10.1111/jocd.14035
Furer V, Zisman D, Kibari A, et al. Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series. Rheumatology (Oxford, England). 2021 [Epub ahead of print].
DOI: https://doi.org/10.1093/rheumatology/keab345
Maranini B, Ciancio G, Cultrera R, Govoni M. Herpes zoster infection following mRNA COVID-19 vaccine in a patient with ankylosing spondylitis. Reumatismo. 2021; 73: 174-6.
DOI: https://doi.org/10.4081/reumatismo.2021.1445
How to Cite
Mohamadzadeh, D., Assar, S., Pournazari, M., Soufivand, P., & Danaei, S. (2022). Disseminated cutaneous herpes simplex infection after COVID-19 vaccination in a rheumatoid arthritis patient: a case report and review. Reumatismo, 74(2). https://doi.org/10.4081/reumatismo.2022.1489
Copyright (c) 2022 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- A. Gava, A. Furlan, F. Navaglia, M. Miorin, M. Razetti, D. Basso, M. Plebani, L. Punzi, Utility of denaturing high performance liquid chromatography (DHPLC) for the diagnosis of mevalonate kinase deficiency in periodic fevers of autoinflammatory nature suspicion , Reumatismo: Vol. 61 No. 3 (2009)
- K.V. Ilic, M. Sefik-Bukilica, S. Jankovic, N. Vujasinovic-Stupar, Efficacy and safety of two generic copies of nimesulide in patients with low back pain or knee osteoarthritis , Reumatismo: Vol. 61 No. 1 (2009)
- Ombretta Di Munno, Andrea Delle Sedie, Glucocorticoid-induced osteoporosis and rheumatic diseases. Pathogenesis, prevention and treatment , Reumatismo: Vol. 58 No. 1 (2006)
- G. Lapadula, Biologic therapy with anti-TNFa in spondyloarthritides and other autoimmune diseases , Reumatismo: Vol. 57 No. s4 (2005)
- M. Favero, F. Schiavon, L. Riato, V. Carraro, L. Punzi, Septic arthritis: a 12 years retrospective study in a rheumatological university clinic , Reumatismo: Vol. 60 No. 4 (2008)
- S. Monti, R. Caporali, Chronic pain: the burden of disease and treatment innovations , Reumatismo: Vol. 67 No. 2 (2015)
- L. Andreoli, C. Nalli, M. Motta, G.L. Norman, W.L. Binder, M. Nuzzo, M. Frassi, A. Lojacono, T. Avcin, P.L. Meroni, A. Tincani, Subpopulations of anti-β2glycoprotein I antibodies with different pathogenic potential: fine specificity against the domains of β2glycoprotein I , Reumatismo: Vol. 62 No. 3 (2010)
- P. Lazzarin, G. Pasero, P. Marson, A. Cecchetto, G. Zanchin, Takayasu’s arteritis. A concise review and some observations on a putative case reported by Giovanni Battista Morgagni (1761) , Reumatismo: Vol. 57 No. 4 (2005)
- G.L. Erre, G. Passiu, Antioxidant effect of Iloprost: current knowledge and therapeutic implications for systemic sclerosis , Reumatismo: Vol. 61 No. 2 (2009)
- Ciro Manzo, Marco Isetta, After what time interval are we justified to diagnose immune checkpoint inhibitor-mediated polymyalgia rheumatica? , Reumatismo: Early Access
<< < 7 8 9 10 11 12 13 14 15 16 > >>
You may also start an advanced similarity search for this article.
